On Wednesday, MoonLake Immunotherap received an upgrade to its Relative Strength (RS) Rating, from 61 to 75.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves. See if MoonLake Immunotherap can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
MoonLake Immunotherap is not currently offering a proper buying opportunity. See if the stock goes on to build a promising consolidation that could kick off a new climb.
MoonLake Immunotherap reported 0% earnings growth last quarter. Sales rose 0%.
The company earns the No. 179 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
